Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin

Blood

Volumn 101, Issue 5, 2003, Pages 2001-2007

  Witt, Olaf ^a   Mönkemeyer, Sven ^a   Rönndahl, Gabi ^a   Erdlenbruch, Bernhard ^a   Reinhardt, Dirk ^a   Kanbach, Katrin ^a   Pekrun, Arnulf ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUTYRIC ACID; CYCLO DEXTRO PROLYLALANYL 2 AMINO 8 OXO 9,10 EPOXYDECANOIC ACID; GAMMA GLOBIN; HEMOGLOBIN F; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; ISOBUTYRIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [PYRIDIN 3 YLMETHOXYCARBONYL)AMINOMETHYL]BENZAMIDE; SYNAPTOPHYSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; ERYTHROLEUKEMIA CELL; GENE EXPRESSION; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

EID: 0037369256     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2617     Document Type: Article

References (34)

1. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341:99-109.
2. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol. 2001;38:367-373.
3. Rodgers GP, Sauntharajah Y. Advances in experimental treatment of beta-thalassaemia. Exp Opin Invest Drugs. 2001;10:925-934.
4. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med. 1993;328:81-86.
5. Blau CA, Constantoulakis P, Shaw CM, Stamatoyannopoulos G. Fetal hemoglobin induction with butyric acid: efficacy and toxicity. Blood. 1993;81:529-537.
6. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 1994;84:339-343.
7. Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med. 1995;332:1606-1610.
8. Reich S, Bührer C, Henze G, et al. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. Blood. 2000;96:3357-3363.
9. Cousens LS, Gallwitz D, Alberts BM. Different accessibilities in chromatin to histone acetylase. J Biol Chem. 1978;254:1716-1723.
10. Candido EMP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978;14:105-113.
11. Doenecke D, Gallwitz D. Acetylation of histones in nucleosomes. Mol Cell Biochem. 1982;44:113-128.
12. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MSS. Induction of gamma-globin by histone deacetylase inhibitors. Blood. 1997;5:2075-2083.
13. Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. 1987;47:3688-3691.
14. Witt O, Albig W, Doenecke D. Transcriptional regulation of the human replacement histone gene H3.3B. FEBS Lett. 1997;408:255-260.
15. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174-17179.
16. Han JW, Ahn SH, Park SH, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21 WAF1/Cip1 and gelsolin. Cancer Res. 2000;60:6068-6074.
17. Witt O, Sand K, Pekrun A. Butyrate induced erythroid differentiation of human K562 cells involves inhibition of ERK and activation of p38 MAP kinase-pathways. Blood. 2000;95:2391-2396.
18. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739-746.
19. Cuenda A, Rouse J, Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364:229-233.
20. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279:1453-1461.
21. Favata M, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen activated protein kinase kinase. J Biol Chem. 1998;273:18623-18632.
22. Hansen JC, Tse C, Wolffe AP. Structure and function of the core histone N-termini: more than meets the eye. Biochemistry. 1998;37:17637-17641.
23. Walia H, Chen HY, Sun JM, Holth LT, Davie JR. Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA. J Biol Chem. 1998;273:14516-14522.
24. Nightinghale KP, Wellinger RE, Sogo JM, Becker PB. Histone acetylation facilitates RNA polymerase II transcription of the Drosophila hsp26 gene in chromatin. EMBO J. 1998;17:2865-2876.
25. Tse C, Sera T, Wolffe AP, Hansen JC. Disruption of higher order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III. Mol Cell Biol. 1998;18:4629-4638.
26. Forsberg EC, Downs KM, Christensen HM, Im H, Nuzzi PA, Bresnick EH. Developmentally dynamic histone acetylation pattern of a tissue-specific chromatin domain. Proc Natl Acad Sci U S A. 2000;97:14494-14499.
27. Smith RD, Li J, Noguchi CT, Schechter AN. Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood. 2000;95:863-869
28. Darkin-Rattray SJ, Gurnett AM, Myers RW, et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci U S A. 1996;93:13143-13147.
29. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001;48(suppl 1):S20-S26.
30. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-139.
31. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726-735.
32. Witt O, Schulze S, Kanbach K, Roth C, Pekrun A. Tumor cell differentiation by butyrate and environmental stress. Cancer Lett. 2001;171:173-182.
33. Nagata Y, Takahashi N, Davis RJ, Todokoro K. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood. 1998;92:1859-1869.
34. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood. 1999;94:853-863.